Tessera Defense and Homeland Security (HLSQ) AI Stock Analysis

• Market Cap: $2.64M
• Dividend Yield: N/A
• Average Volume (3M): 400.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.13
• Revenue Growth: N/A
• EPS Growth: -12.54%
• Country: US
• Employees: 20
• Sector: Industrials
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -200.60
• Shares Outstanding: 2,730,000
• 10 Day Avg. Volume: 949,150
• 30 Day Avg. Volume: 400,880
• PEG Ratio: <0.01
• Price to Book (P/B): -100.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.95
• Enterprise Value/Market Cap: <0.01
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: >-0.01
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -58.5
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.69 ▲(427.69% Upside)
• Action: Reiterated
• Date: 09/17/26

Positive Factors

Low financial leverage

Very low current leverage limits interest burden and reduces dependence on debt financing. This gives management greater flexibility to allocate capital toward integration and commercialization, although continued losses still make the overall balance sheet dependent on future funding.

Negative Factors

Minimal revenue and deep losses

The very small revenue base remains far below the company’s operating cost structure, producing sharply negative margins and substantial losses. Until the strategic transition generates meaningful sales, profitability and the ability to scale without additional capital remain unproven.

Tessera Defense and Homeland Security Business Overview & Revenue Model

Company Description

Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as...

Read more

Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as...

How the Company Makes Money

BiomX is a clinical-stage company and, as such, it generally does not rely on recurring product sales; instead, its ability to generate revenue is primarily tied to funding and collaboration-based sources. Key ways the company may generate revenue...

Read more

BiomX is a clinical-stage company and, as such, it generally does not rely on recurring product sales; instead, its ability to generate revenue is primarily tied to funding and collaboration-based sources. Key ways the company may generate revenue...

Tessera Defense and Homeland Security Financial Statement Overview

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Tessera Defense and Homeland Security Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLSQ, the sentiment is Negative. The current price of 0.13 is below the 20-day moving average (MA) of 1.38, below the 50-day MA of 1.73, and below the 200-day MA of 21.86, indicating a bearish trend. The MACD of -0.19 indicates Negative momentum. The RSI at 30.64 is Neutral, neither overbought nor oversold. The STOCH value of 12.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HLSQ.

Tessera Defense and Homeland Security Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
IMRN	51 Neutral	$10.08M	-3.41	-31.88%	―	10.41%	40.27%
LPCN	46 Neutral	$18.01M	-1.16	-64.75%	―	-62.70%	-121.27%
CANF	43 Neutral	$6.99M	-0.32	-182.88%	―	―	―
HLSQ	41 Neutral	$2.64M	>-0.01	-947.73%	―	―	-12.54%

Tessera Defense and Homeland Security Corporate Events